Improving access to clinical trials
Clinical trials are the single best way to turn advances in science into patient benefits. The ICR has a vision that a suitable trial should be made available for every person with cancer who wants to be part of one.
Expanding trial access – ICR report
Our 2021 report, Clinical trials in cancer, reveals the impact of the Covid-19 pandemic on cancer trials and highlights longstanding barriers to expanding clinical trial access to more people with cancer. But Covid-19 also offers clues to a recovery that can get new treatments to cancer patients more quickly.
News: Cancer trial recruitment drops by 60 per cent during pandemic
The number of cancer patients entering clinical trials has plummeted during the pandemic – denying many thousands the latest treatment options and delaying drug development. Here, cancer experts set out their findings about the barriers to carrying out clinical trials in the UK and proposals for boosting participation.Latest ICR News
Newly discovered role for cancer-linked protein exposes vulnerability in tumour cells
Scientists have uncovered a previously hidden role for a protein frequently mutated in cancer, showing that it helps maintain the stability of the genome at some of its most vulnerable sites.
New understanding of enzyme regulating gene expression could inform future cancer therapies
Scientists have uncovered how an important cellular enzyme is regulated, revealing new insights into the fundamental biological processes controlling gene expression and opening up potential avenues for future cancer drug development.
Local anaesthetic shows promise in blocking childhood cancer spread, study finds
A drug best known for numbing the skin before minor medical procedures may hold unexpected promise in tackling one of the most aggressive childhood cancers.
New insights reveal why some triple-negative breast cancers resist treatment
A team co-led by researchers at The Institute of Cancer Research, London, has uncovered how treatment-resistant cancer cells may drive poor outcomes for people with triple-negative breast cancer (TNBC), one of the most aggressive forms of the disease.